医学
达比加群
心房颤动
急性冠脉综合征
内科学
心脏病学
禁忌症
阿哌沙班
拜瑞妥
氯吡格雷
华法林
冲程(发动机)
经皮冠状动脉介入治疗
传统PCI
颅内出血
直接凝血酶抑制剂
重症监护医学
临床试验
心肌梗塞
经皮
肾功能
血小板聚集抑制剂
急性肾损伤
作者
Felicita Andreotti,Adhithya N. Balaji,Luigi Cappannoli,Lidia Megaro,Francesco Landi,Francesco Burzotta
出处
期刊:Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine
[Medycyna Praktyczna]
日期:2026-06-08
卷期号:136 (7-8)
被引量:2
摘要
Direct oral anticoagulants (DOACs) have been available since 2008, boosting appropriate anticoagulation and reducing intracranial hemorrhages, as compared with warfarin therapy. However, for older individuals with atrial fibrillation (AF) and comorbidities, decisions on DOAC therapy may be challenging. In frail, stable‑on‑warfarin patients, the FRAIL‑AF (Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation) trial reported increased relevant bleeding after switching to a DOAC. Subsequent individual patient‑data analyses of 4 pivotal DOAC‑vs‑warfarin AF trials confirmed the overall advantages of DOACs over warfarin even among older, frail, warfarin‑experienced individuals. Advanced age should not exclude the use of any DOAC for AF, but care is needed to adjust the doses, when indicated, particularly based on renal function. All DOACs undergo variable renal clearance and, in Europe, creatinine clearance below 30 ml/min contraindicates dabigatran, and below 15 ml/min factor‑Xa inhibitors. AF patients on DOACs presenting with acute coronary syndrome and / or requiring percutaneous coronary interventions are generally managed with additional dual antiplatelet therapy for 1-4 weeks, followed by clopidogrel plus DOAC for up to 1 year. AF patients with chronic coronary syndromes should generally receive a DOAC without additional antiplatelet therapy, as this abates major bleeding and improves cardiovascular survival without evidence of increased ischemic risk. For AF patients who develop acute ischemic stroke, recent exposure to a DOAC is a relative contraindication to intravenous thrombolysis, but the latter may be considered when clinically‑relevant anticoagulation can be excluded. Finally, for AF patients who develop nonsevere hemorrhagic stroke during DOAC therapy, resuming a DOAC to prevent ischemic strokes is counterbalanced by considerably enhanced major bleeding, including intracranial.
科研通智能强力驱动
Strongly Powered by AbleSci AI